Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
复制标题
DOI：
10.2169/internalmedicine.56.7908
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Maruyama S
中科院分区：
文献类型：
--
作者：
Katsuno T;Ozaki T;Kim H;Kato N;Suzuki Y;Akiyama S;Ishimoto T;Kosugi T;Tsuboi N;Ito Y;Maruyama S
迄今为止，尚未建立公认的难治性膜性肾病（MN）治疗方法。最近，一些报告表明利妥昔单抗作为一种新的治疗选择的功效。然而，关于利妥昔单抗治疗亚洲人群特发性 MN (IMN) 的报道仅有少数。我们介绍了三名 IMN 患者的病例，他们在对常规疗法（包括皮质类固醇、环孢素、环磷酰胺、咪唑立宾和吗替麦考酚酯）没有反应后接受单剂量利妥昔单抗治疗。尽管一名病例没有出现缓解，但另外两例则达到了完全或不完全缓解。因此，利妥昔单抗可能是 IMN 的有益治疗选择。
To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.
登录
查看更多内容
影响因子：
4.2
作者：
Cravedi, Paolo;Sghirlanzoni, Maria Chiara;Ruggenenti, Piero
通讯作者：
Ruggenenti, Piero
影响因子：
2.3
作者：
Nishi S;Ubara Y;Utsunomiya Y;Okada K;Obata Y;Kai H;Kiyomoto H;Goto S;Konta T;Sasatomi Y;Sato Y;Nishino T;Tsuruya K;Furuichi K;Hoshino J;Watanabe Y;Kimura K;Matsuo S
通讯作者：
Matsuo S
影响因子：
2.5
作者：
Fervenza, Fernando C.;Canetta, Pietro A.;Cattran, Daniel C.
通讯作者：
Cattran, Daniel C.
影响因子：
19.6
作者：
Fervenza, F. C.;Cosio, F. G.;Cattran, D. C.
通讯作者：
Cattran, D. C.
影响因子：
168.9
作者：
Remuzzi, G;Chiurchiu, C;Ruggenenti, P
通讯作者：
Ruggenenti, P